GlassScriptPhysician profile
Chantelle Iloreta
NPI 1225745029
$1,896.15
in general payments reported to CMS, 2019-2025
21 companies · $1,201 in 2025
The $1,201 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $695 · 2025: $1,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,896.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $302.40 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $274.89 | 2025 | |
| Corcept Therapeutics | $230.24 | 2024-2025 | Korlym |
| Lilly USA, LLC | $184.55 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $163.87 | 2024-2025 | Repatha, Otezla, Evenity |
| Intra-Sana Laboratories | $138.48 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Exact Sciences Corporation | $138.32 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.79 | 2024-2025 | Jardiance |
| Pfizer INC. | $54.97 | 2024-2025 | |
| Astellas Pharma US INC | $54.72 | 2025 | Veozah |
| Boston Scientific Corporation | $43.94 | 2025 | General - Brady, General - Pain Management |
| Sanofi-Aventis U.S. LLC | $37.70 | 2024-2025 | |
| Tactile Systems Technology INC | $36.63 | 2025 | Nimbl, Flexitouch Plus |
| Abbott Laboratories | $23.22 | 2025 | Freestyle Libre 3 |
| Viiv Healthcare Company | $22.33 | 2024 | Apretude |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $16.06 | 2025 | Nalu Neurostimulation System |
| Biomerieux INC | $15.00 | 2025 | |
| Impulse Dynamics (USA) INC. | $14.99 | 2024 | Optimizer |
| Aimmune Therapeutics, INC. | $13.79 | 2024 | |
| Currax Pharmaceuticals LLC | $13.66 | 2024 | Contrave |
| Amneal Pharmaceuticals LLC | $13.60 | 2025 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chantelle Iloreta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.